{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"95.9","value":"52.4"}]}],"title":"Predose Cycle 2 Day 1 (n=419)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"80.6","value":"76.6"}]}],"title":"Predose Cycle3 Day 1 (n=386)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"92.2","value":"94.5"}]}],"title":"Predose Cycle 4 Day 1 (n=344)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"90","value":"101"}]}],"title":"Predose Cycle 5 Day 1 (n=297)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"80","value":"98.5"}]}],"title":"Predose Cycle 6 Day 1 (n=262)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"545"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Necitumumab + Gemcitabine + Cisplatin\n\nNecitumumab: 800 mg I.V. infusion on Days 1 and 8 of every 3 week cycle.\n\nContinues until progressive disease, toxicity, noncompliance, or withdrawal.\n\nGemcitabine: 1250 mg/m2 on Days 1 and 8 of every 3 week cycle.\n\nContinues for a maximum of six cycles.\n\nCisplatin: 75 mg/m2 IV on Day 1 of every 3 week cycle.\n\nContinues for a maximum of six cycles.","id":"OG000","title":"Necitumumab + Gemcitabine + Cisplatin"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All randomized participants who received at least one dose of study drug and had evaluable data for PK.","reportingStatus":"POSTED","timeFrame":"Day 1 of Cycle 2, 3, 4, 5 and 6 Prior to Necitumumab Drug Infusion, Up to 24 Months","title":"Pharmacokinetics (PK): Minimum Concentration (Cmin) of Necitumumab","type":"SECONDARY","unitOfMeasure":"micrograms/milliliter (ug/mL)"}